These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates. Polito M; d'Anzeo G; Conti A; Muzzonigro G BJU Int; 2012 Dec; 110(11 Pt C):E954-7. PubMed ID: 23078100 [TBL] [Abstract][Full Text] [Related]
8. Vasoactive intracavernous pharmacotherapy. Sidi AA Urol Clin North Am; 1988 Feb; 15(1):95-101. PubMed ID: 2449756 [TBL] [Abstract][Full Text] [Related]
9. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. Zorgniotti AW; Lefleur RS J Urol; 1985 Jan; 133(1):39-41. PubMed ID: 2578067 [TBL] [Abstract][Full Text] [Related]
11. [Long-term results of the treatment with intracavernous injection of vasoactive drugs]. Rodríguez Vela L; Gonzalvo Ibarra A; Gil Martínez P; Benejan Gual J; Cuesta Presedo JM; Ríoja Sanz LA Arch Esp Urol; 1996 Apr; 49(3):257-69. PubMed ID: 8702347 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for an early increase in dose of vasoactive agents for intracavernous pharmacotherapy. Kim SC; Seo KK; Park BD; Lee SW Urol Int; 2000; 65(4):204-7. PubMed ID: 11112870 [TBL] [Abstract][Full Text] [Related]
13. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476 [TBL] [Abstract][Full Text] [Related]
14. Experience in the management of erectile dysfunction using the intracavernosal self-injection of vasoactive drugs. Watters GR; Keogh EJ; Earle CM; Carati CJ; Wisniewski ZS; Tulloch AG; Lord DJ J Urol; 1988 Dec; 140(6):1417-9. PubMed ID: 3193507 [TBL] [Abstract][Full Text] [Related]
15. Intracavernous injection of papaverine, phentolamine and phenoxybenzamine. Pettirossi O; Serenelli G Acta Urol Belg; 1988; 56(2):211-9. PubMed ID: 3400527 [No Abstract] [Full Text] [Related]
16. Oral tadalafil administration plus low dose vasodilator injection: a novel approach to erection induction for penile color duplex ultrasound. Yang Y; Hu JL; Ma Y; Wang HX; Chen Z; Xia JG; Wang YX; Huang YR; Chen B J Urol; 2011 Jul; 186(1):228-32. PubMed ID: 21575959 [TBL] [Abstract][Full Text] [Related]
17. [Dose adaptation during training of intracavernous self-injections of prostaglandin E1]. Staerman F; Veilhan LA; Guiraud P; Coeurdacier P; Cipolla B; Lobel B Prog Urol; 1996; 6(4):564-8. PubMed ID: 8924934 [TBL] [Abstract][Full Text] [Related]
18. Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. The Sildenafil Multicenter Study Group. Giuliano F; Montorsi F; Mirone V; Rossi D; Sweeney M J Urol; 2000 Sep; 164(3 Pt 1):708-11. PubMed ID: 10953130 [TBL] [Abstract][Full Text] [Related]
19. [Retrospective study on the incidence and cause of drop-out during intracavernous pharmaco-prosthesis therapy]. Giammusso B; Motta M Arch Ital Urol Androl; 2002 Mar; 74(1):27-31. PubMed ID: 12053447 [TBL] [Abstract][Full Text] [Related]
20. Follow up outcome of intracavernous papaverine. al-Juburi AZ; O'Donnell PD J Ark Med Soc; 1990 Mar; 86(10):383-5. PubMed ID: 2138146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]